17P deletion and TP53 gene mutation (17P/TP53) testing behaviour and treatment patterns for chronic lymphocytic leukemia (CLL) patients in France, Germany, Italy, Spain and UK (EU5)

被引：1
|
作者：
Canta, F. A. Bermudez [1 ]
Mitrofan, L. [2 ]
Karanis, Y. B. [1 ]
Mistry, H. [1 ]
Anger, C. [1 ]
机构：
[1] IMS Hlth, Global Oncol, London, England
[2] IMS Hlth, Global Oncol, La Defence, France
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw375.14
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
919P
引用
收藏
页数：1
相关论文
共 50 条
  • [1] How best to manage patients with chronic lymphocytic leuekmia with 17p deletion and/or TP53 mutation?
    Tam, Constantine S.
    Stilgenbauer, Stephan
    LEUKEMIA & LYMPHOMA, 2015, 56 (03) : 587 - 593
  • [2] Prognostic Impact of TP53 Mutation in Combination with Chromosome 17p Deletion in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
    Yun, Seongseok
    Sandoval-Sus, Jose
    Knepper, Todd C.
    Teer, Jamie
    Chavez, Julio C.
    Pinilla-Ibarz, Javier
    BLOOD, 2017, 130
  • [3] Aberrant Nuclear p53 Expression Predicts Hemizygous 17p (TP53) Deletion in Chronic Lymphocytic Leukemia
    Chang, Hong
    Jiang, Allan M.
    Qi, Connie X. Y.
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2010, 133 (01) : 70 - 74
  • [4] Impact of TP53 mutation and 17p deletion in mantle cell lymphoma
    Halldorsdottir, A. M.
    Lundin, A.
    Murray, F.
    Mansouri, L.
    Knuutila, S.
    Sundstrom, C.
    Laurell, A.
    Ehrencrona, H.
    Sander, B.
    Rosenquist, R.
    LEUKEMIA, 2011, 25 (12) : 1904 - 1908
  • [5] Treatment Outcomes Among Chronic Lymphocytic Leukemia Patients with 17p Deletion or TP53 Mutation in Argentina: A Retrospective Chart Review
    Pavlovsky, Miguel A.
    Sail, Kavita
    Chaves, Leonardo Passos
    Kamalakar, Rajesh
    Ma, Xiaojing
    Brandalise, Patricia
    Chiattone, Carlos
    BLOOD, 2017, 130
  • [6] Impact of TP53 mutation and 17p deletion in mantle cell lymphoma
    A M Halldórsdóttir
    A Lundin
    F Murray
    L Mansouri
    S Knuutila
    C Sundström
    A Laurell
    H Ehrencrona
    B Sander
    R Rosenquist
    Leukemia, 2011, 25 : 1904 - 1908
  • [7] DOSE DENSE HIGH DOSE METHYLPREDNISOLONE (HDMP) AND RITUXIMAB (RTX) ARE EFFECTIVE IN RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH 17P DELETION (17P DEL) / TP53 MUTATION
    Pileckyte, R.
    Valceckiene, V.
    Zvirblis, T.
    Griskevicius, L.
    HAEMATOLOGICA, 2012, 97 : 525 - 526
  • [8] Utilization of Targeted Exome Sequencing to Determine Implications of TP53 Mutation Status in Relation to 17p Deletion in Chronic Lymphocytic Leukemia (CLL)
    Chaudhury, Ateefa
    Chavez, Julio C.
    Pinilla-Ibarz, Javier
    BLOOD, 2014, 124 (21)
  • [9] Clinical Characteristics and Overall Survival Among Acute Myeloid Leukemia (AML) Patients with TP53 Gene Mutation (TP53m) or Chromosome 17p Deletion (17p del)
    Daver, Naval
    Iqbal, Shahed
    Huang, Julie
    Renard, Camille
    Lin, Joyce
    Pan, Harry
    Xing, Guan
    Pan, Yang
    Ramsingh, Giri
    BLOOD, 2022, 140 : 1445 - 1446
  • [10] No benefit from adding rituximab to ibrutinib in relapsed or refractory chronic lymphocytic leukemia or 17p deletion/TP53 mutation
    Calleja, Anne
    HEMATOLOGIE, 2019, 25 (03): : 131 - 132
12345